7 things to know before Saroja Pharma Industries India Limited

Overview of company:

• Saroja Pharma Industries India Limited IPO was incorporated in 2019.
• The company is involved in trading, exporting, and supplying Specialty Chemicals & Active Pharmaceutical Ingredients (API).

Product Categories: The company deals in three distinct product categories:

1. Chemical: Trading of various chemicals.
2. Pharma Intermediary: Supply of pharmaceutical intermediaries.
3. Veterinary Pharma API: Providing APIs for veterinary pharmaceuticals.

Product Range:

• The company offers a range of products including Liquide Bromine, used as an agro-intermediate.
• Ethyl Acetate, which serves as an API solvent.
• Various pharmaceuticals intended for human and veterinary drugs.
• Some of these products also function as API solvents.

Role of APIs:

• APIs, or Active Pharmaceutical Ingredients, are the primary components used in creating finished dosages like capsules, tablets, liquids, and other forms of dosage.
• APIs are combined with other APIs or inactive ingredients to produce the final pharmaceutical products.

Export Markets:

• The company primarily exports its products to countries including Pakistan, Egypt, Russia, Jordan, Hong Kong, and Singapore.

Competitive Strength:

• Experienced Promoters and Management Team
• Scalable Business Model
• Wide and diverse range of product offerings
• Diversified business operations and revenue base

Financials of the Company:

Period Ended	31 Mar 2021	31 Mar 2022	31 Mar 2023
Assets	822.39	1,551.19	2,133.99
Revenue	3,674.67	5,595.67	5,035.09
Profit After Tax	73.13	114.01	106.06
Net Worth	93.59	402.60	508.66
Reserves and Surplus	92.59	380.02	215.09
Total Borrowing	301.77	613.88	1,018.86

Objects of the Issue:

Utilization of Proceeds from Fresh Issue: The proceeds generated from the Fresh Issue will be allocated for the following purposes:

1. Setting up a Manufacturing Unit: The funds will be used to establish a new manufacturing facility.
2. Repayment of Unsecured Loans: Part of the proceeds will be utilized to repay existing unsecured loans.
3. Public Issue Expenses: The funds will also cover the expenses related to the public issue.

Saroja Pharma Industries IPO Review (I am Avoiding)

SPIIL is presently engaged in trading specialty chemicals and pharma APIs. Despite its plans to venture into manufacturing, its financial performance has displayed inconsistency in the reported periods. The indicated asking price seems ambitious given its historical financial data. The limited equity post-IPO suggests a lengthier timeline for transitioning to the mainboard. Opting to avoid this investment, characterized as a “High Risk/Low Return” proposition, might be a prudent choice.

SAROJA Pharma Industries IPO Subscription Status (Bidding Detail)

As of August 31, 2023:

• The Saroja Pharma Industries IPO has been subscribed 0.79 times in total.
• In the retail category, the subscription is 1.58 times.
• In the Other category, the subscription is 0.11 times.

Check Day by Day Subscription Details (Live Status)

Saroja Pharma Industries SME GMP

The IPO till now there is no data is currently available.

check live Gmp details(status)

For more IPO related content like this stay tuned with ipohunts.

for previous financial blog about CPS sharpers click here.

If you are Interested in cricket buzzers and updates then make sure to check out crikzone.

if you are interested in Politics ,Football, technology make sure to check out blogsroom.